Halozyme Therapeutics, Inc. Net Income 2009–2025
Halozyme Therapeutics, Inc. reported $316.89M of net income for fiscal 2025. That was 28.6% lower than fiscal 2024. Compared with fiscal 2020, the change was +145.5%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $316.89M | 22.7% | -28.6% |
| FY 2024 | $444.09M | 43.7% | +57.7% |
| FY 2023 | $281.59M | 34.0% | +39.3% |
| FY 2022 | $202.13M | 30.6% | -49.8% |
| FY 2021 | $402.71M | 90.8% | +212.0% |
| FY 2020 | $129.09M | 48.2% | +278.7% |
| FY 2019 | $-72.24M | -36.9% | +10.1% |
| FY 2018 | $-80.33M | -52.9% | -227.6% |
| FY 2017 | $62.97M | 19.9% | +161.1% |
| FY 2016 | $-103.02M | -70.2% | -219.6% |
| FY 2015 | $-32.23M | -23.9% | +52.9% |
| FY 2014 | $-68.38M | -90.8% | +18.1% |
| FY 2013 | $-83.48M | -152.3% | -55.9% |
| FY 2012 | $-53.55M | -126.5% | -170.9% |
| FY 2011 | $-19.77M | -35.2% | +62.9% |
| FY 2010 | $-53.24M | -390.8% | +8.8% |
| FY 2009 | $-58.36M | -426.9% | — |
Source: Halozyme Therapeutics, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open HALO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Halozyme Therapeutics, Inc. reported $316.89M of net income for fiscal 2025. That was 28.6% lower than fiscal 2024. Compared with fiscal 2020, the change was +145.5%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s net income?
Halozyme Therapeutics, Inc. (HALO) reported net income of $316.89M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.